Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference-Reference-Cited by-同舟云学术

Management and treatment of glomerular diseases (part 1): conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference

Published:2020-02-08 Issue:2 Volume:24 Page:22-41
ISSN:2541-9439
Container-title:Nephrology (Saint-Petersburg)
language:
Short-container-title:Nefrologiâ (St.-Peterbg.)

Author:

Floege Jűrgen¹,Barbour Sean J.²,Cattran Daniel C.³,Hogan Jonathan J.⁴,Nachman Patrick H.⁵,Tang Sydney C.W.⁶,Wetzels Jack F.M.⁷,Cheung Michael⁸,Wheeler David C.⁹,Winkelmayer Wolfgang C.¹⁰,Rovin Brad H.¹¹

Affiliation:

1. Rheinisch-Westfälische Technische Hochschule University of Aachen

2. British Columbia Provincial Renal Agency; University of British Columbia; St. Paul’s Hospital

3. University Health Network

4. University of Pennsylvania

5. University of Minnesota

6. The University of Hong Kong; Queen Mary Hospital

7. Radboud University Medical Center

8. KDIGO

9. University College London

10. Baylor College of Medicine

11. The Ohio State University

Abstract

The Kidney Disease: Improving Global Outcomes (KDIGO) initiative organized a Controversies Conference on glomerular diseases in November 2017. The conference focused on the 2012 KDIGO guideline with the aim of identifying new insights into nomenclature, pathogenesis, diagnostic work-up, and, in particular, therapy of glomerular diseases since the guideline’s publication. It was the consensus of the group that most guideline recommendations, in particular those dealing with therapy, will need to be revisited by the guideline-updating Work Group. This report covers general management of glomerular disease, IgA nephropathy, and membranous nephropathy.

Publisher

Non-profit organization Nephrology

Subject

Nephrology

Reference112 articles.

1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2012;2:139–274. doi: 10.1038/kisup.2012.9

2. Sethi S, D’Agati VD, Nast CC et al. A proposal for standardized grading of chronic changes in native kidney biopsy specimens. Kidney Int 2017;91:787–789. doi: 10.1016/j.kint.2017.01.002

3. D’Agati VD, Mengel M. The rise of renal pathology in nephrology: structure illuminates function. Am J Kidney Dis 2013;61:10161025. doi: 10.1053/j.ajkd.2012.12.019

4. Larsen CP, Messias NC, Silva FG et al. Determination of primary versus secondary membranous glomerulopathy utilizing phospholipase A2 receptor staining in renal biopsies. Mod Pathol 2013;26:709–715. doi: 10.1038/modpathol.2012.207

5. Dai H, Zhang H, He Y. Diagnostic accuracy of PLA2R autoantibodies and glomerular staining for the differentiation of idiopathic and secondary membranous nephropathy: an updated meta-analysis. Sci Rep 2015;5:8803. doi: 10.1038/srep08803

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Manejo de la nefropatía membranosa idiopática con ciclofosfamida endovenosa;Revista Repertorio de Medicina y Cirugía;2022-07-14

2. Risk of nephrogenic systemic fibrosis (NSF) in oncology patients receiving gadoxetic acid and updated risk of estimate of NSF in patients receiving gadoxetic acid with moderate and severe renal impairment;Abdominal Radiology;2022-01-07

3. Reduction in proteinuria after immunosuppressive therapy and long-term kidney outcomes in patients with immunoglobulin A nephropathy;The Korean Journal of Internal Medicine;2021-09-01

4. A PLA2R-IgG4 Antibody-Based Predictive Model for Assessing Risk Stratification of Idiopathic Membranous Nephropathy;Journal of Healthcare Engineering;2021-08-31

5. Preliminary study on the application of renal ultrasonography radiomics in the classification of glomerulopathy;BMC Medical Imaging;2021-07-23